The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating

European Neuropsychopharmacology

Volumn 22, Issue 5, 2012, Pages 374-378

  Feifel, David ^a   Shilling, Paul D ^a   Belcher, Annabelle M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Animal models; Antipsychotics; Brown Norway; Prepulse inhibition; Schizophrenia

Indexed keywords

CARBETOCIN; CLOZAPINE; OXYTOCIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; AUDITORY RESPONSE; BROWN NORWAY RAT; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; GENETIC DISORDER; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORY GATING; STARTLE REFLEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MODELS, ANIMAL; OXYTOCIN; RATS; RATS, INBRED BN; SENSORY GATING; STARTLE REACTION; TREATMENT OUTCOME;

EID: 84859214579     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.09.004     Document Type: Article

References (27)

1. Beckmann H., Lang R.E., Gattaz W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 1985, 10(2):187-191.
2. Braff D.L. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr. Top. Behav. Neurosci. 2010, 4:349-371.
3. Caldwell H.K., Stephens S.L., Young, W.S. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol. Psychiatry 2009, 14(2):190-196.
4. Chaviaras S., Mak P., Ralph D., Krishnan L., Broadbear J.H. Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology (Berl) 2010, 210(1):35-43.
5. Conti L.H., Costill J.E., Flynn S., Tayler J.E. Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain. Behav. Neurosci. 2005, 119(4):1052-1060.
6. Dvorska I., Brust P., Hrbas P., Ruhle H.J., Barth T., Ermisch A. On the blood-brain barrier to peptides: effects of immobilization stress on regional blood supply and accumulation of labelled peptides in the rat brain. Endocr. Regul. 1992, 26(2):77-82.
7. Engstrom T., Barth T., Melin P., Vilhardt H. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur. J. Pharmacol. 1998, 355(2-3):203-210.
8. Ermisch A., Ruhle H.J., Landgraf R., Hess J. Blood-brain barrier and peptides. J. Cereb. Blood Flow Metab. 1985, 5(3):350-357.
9. Feifel D., Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 1999, 141(1):93-98.
10. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 2010, 68(7):678-680.
11. Feifel D., Shilling P.D., Melendez G. Clozapine and PD149163 elevate prepulse inhibition In Brown Norway rats. Behavioral Neuroscience 2011, 125(2):268-272.
12. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156(2-3):117-154.
13. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res. 2008, 98(1-3):247-255.
14. Harony H., Wagner S. The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neurosignals 2010, 18(2):82-97.
15. Insel T.R. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010, 65(6):768-779.
16. Klenerova V., Krejci I., Sida P., Hlinak Z., Hynie S. Modulary effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field. J. Physiol. Pharmacol. 2009, 60(2):57-62.
17. Klenerova V., Krejci I., Sida P., Hlinak Z., Hynie S. Oxytocin and carbetocin effects on spontaneous behavior of male rats: modulation by oxytocin receptor antagonists. Neuro Endocrinol. Lett. 2009, 30(3):335-342.
18. Lee P.R., Brady D.L., Shapiro R.A., Dorsa D.M., Koenig J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005, 30(10):1883-1894.
19. Linkowski P., Geenen V., Kerkhofs M., Mendlewicz J., Legros J.J. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur. Arch. Psychiatry Neurol. Sci. 1984, 234(3):162-165.
20. Macdonald K., Macdonald T.M. The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv. Rev. Psychiatry 2010, 18(1):1-21.
21. Page G.H. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG 2010, 117(13):1665. author reply 1665-1666.
22. Palmer A.A., Dulawa S.C., Mottiwala A.A., Conti L.H., Geyer M.A., Printz M.P. Prepulse startle deficit in the brown norway rat: a potential genetic model. Behav. Neurosci. 2000, 11(2):374-388.
23. Perry W., Minassian A., Lopez B., Maron L., Lincoln A. Sensorimotor gating deficits in adults with autism. Biol. Psychiatry 2007, 61(4):482-486.
24. Rubin L.H., Carter C.S., Drogos L., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 2010, 124(1-3):13-21.
25. Sala M., Braida D., Lentini D., Busnelli M., Bulgheroni E., Capurro V., et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol. Psychiatry 2011, 69(9):875-882.
26. Swerdlow N.R., Braff D.L., Taaid N., Geyer M.A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry 1994, 51(2):139-154.
27. Swerdlow N.R., Breier M., Mora A.B., Ko D., Shoemaker J.M. A novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating. Pharmacol. Biochem. Behav. 2008, 88(3):280-290.